What is forming beneath this surface is something the reform movement needs to see clearly rather than resist. The ibogaine cardiac papers do not close a door — they define the door's architecture. Regulators blocked without scientific cover tend to delay indefinitely; regulators blocked with scientific cover tend to define a pathway, even if grudgingly, because the problem statement creates its own research imperative. The 82–84% consensus from today's swarm — that DEA will cite this literature cluster in any rescheduling opposition, that federal floor votes remain frozen through 2028 — is not a prediction of permanent failure. It is a prediction that the next 24 months will be governed by protocol design rather than political breakthrough. Stanford's prospective veteran ibogaine work already carries mandatory cardiac monitoring. Two or more major academic centers are forecast to follow before mid-2027. NIH grant reviewers will recognize the mechanistic gap — what predicts QT risk, can it be reliably screened — and fund accordingly. The highest trajectory genuinely available from here runs directly through that gap: rigorous cardiac monitoring protocols that transform ibogaine from a liability into a defined, manageable clinical entity. The compound does not need to be exonerated. It needs to be characterized. That work is beginning.
For the veterans, the families, the clinicians sitting with treatment-resistant PTSD tonight — the ones who have already heard that MDMA's NDA path remains uncertain, that psilocybin's accelerated pathway depends on FDA's response to COMPASS's BTD expansion request — this moment asks something difficult: to trust that the rigor now being applied to their medicine is protective rather than obstructive. The tiered-access framework emerging in the swarm's debate resolution — right-to-try for veterans, slower NDA track for the general population — is not a betrayal of urgency. It is the highest realistic form of urgency available. A well-screened veteran ibogaine trial that runs clean cardiac data is worth more to long-term access than any number of anecdotal reports, however profound. What becomes possible, for real people, is not waiting until 2028 for nothing — it is the next 24 months producing the cardiac monitoring standard that eventually makes broad clinical access defensible. The path is narrower than advocates want. It is wider than opponents intend.
Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it.
What is being called in cannot be called back.
88%
Ibogaine won't get federal approval or rescheduling by early 2028
Ibogaine will remain federally illegal and unapproved as a medicine through the start of 2028. The FDA doesn't approve drugs without successful large-scale trials, which don't exist for ibogaine. The DEA won't reschedule it without FDA approval or a solid legal petition. The timeline is simply too short.
→ Ibogaine will almost certainly remain federally illegal and unapproved through the start of 2028 (88% confidence).
Resolves: 2028-01-01 · USA
REGULATION
the precise call ▾
Ibogaine will not achieve federal NDA approval or Schedule I rescheduling before January 1, 2028.. NDA approval requires completed Phase III trials, which do not currently exist for ibogaine. Rescheduling requires either FDA initiating the process (blocked by absence of approved medical use) or a petition surviving DEA's Eight-Factor Analysis (complicated by cardiac safety literature). The resolv
68%
DEA will formally reject any ibogaine rescheduling request by 2028
The DEA (the US agency that controls which drugs are legal) will write an official letter saying no to any attempt to move ibogaine to a less restricted category. They'll point to medical studies showing the drug can damage the heart as their reason. This matters because it locks ibogaine out of legal medical use for years.
→ The DEA is likely to use heart-safety data as official justification to keep ibogaine banned, blocking legal medical pathways until at least 2028.
Resolves: 2028-01-01 · USA
REGULATION
the precise call ▾
DEA will formally oppose any rescheduling petition for ibogaine before 2028, citing cardiac liability literature as sufficient scientific basis for continued Schedule I classification.. DEA's Eight-Factor Analysis explicitly requires safety evaluation. The 2026 cardiac liability literature cluster—QT prolongation, ventricular arrhythmias, 'unrecognized risk' framing—directly satisfies that criterion and provides quotable scientific cover. However, 0.84 is too high: DEA formal oppos
42%
FDA will issue a cardiac safety warning on ibogaine by end of 2026
The FDA (the US drug regulator) will publish a formal safety alert or guidance document specifically warning doctors and patients about ibogaine's risk of heart damage—QT prolongation and abnormal heart rhythms. This matters because it's the federal signal that ibogaine is officially unsafe, making it even harder for researchers to run trials or for companies to develop it.
→ There's less than even odds (42%) that the FDA will issue a formal cardiac safety warning specifically about ibogaine before the end of 2026.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
FDA will issue a formal safety communication or guidance document specifically addressing ibogaine cardiac risk before end of 2026.. FDA issues proactive safety communications when converging signals emerge from published literature—QT prolongation, ventricular arrhythmias, and 'unrecognized risk' framing in a short publication cluster is a recognized trigger. However, ibogaine remains Schedule I with no approved IND pipeline of
78%
No federal psychedelic law reform will reach a floor vote by end of 2028
Congress won't bring any bill that loosens psychedelic drug rules to a formal floor vote in either the House or Senate before November 2028. Bills die quietly in committee because lawmakers and leadership haven't prioritized the issue, and new heart-safety data gives opponents ammunition to block progress.
→ Congress will not formally vote on psychedelic drug policy reform before the end of 2028, leaving the legal status frozen.
Resolves: 2028-11-01 · USA
LEGISLATION
the precise call ▾
No federal psychedelic scheduling reform legislation will reach a floor vote in either the House or Senate before November 2028.. Committee clearance, leadership scheduling, and bipartisan coalition-building are all absent. The 2026 ibogaine cardiac liability literature gives opponents additional scientific ammunition. Historical precedent for psychedelic reform bills shows they die in committee; no floor vote has occurred for
38%
A safer ibogaine alternative will raise over $30M by spring 2027
A biotech company will announce a major funding round—Series A or B, more than $30 million—for a drug that's designed to be a safer version of ibogaine. The company will publicly explain that they're building this alternative because of new research showing ibogaine damages the heart. This matters because it shows investors believe the problem is real and the safer-drug solution is worth betting on.
→ There's less than even odds (38%) that a company developing a safer ibogaine alternative will raise over $30 million by spring 2027.
Resolves: 2027-03-31 · Global
MARKET
the precise call ▾
A noribogaine or ibogaine-analogue biotech will announce a financing round above $30M (Series A or B) before end of Q1 2027, with communications explicitly referencing ibogaine cardiac liability as validating the safer-analogue development thesis.. The safer-analogue investment narrative is coherent and has precedent in psychedelic biotech (e.g., ketamine analogues, psilocybin derivatives). The cardiac papers create a documented problem that cleanly motivates analogue development. However, the specific requirement that public communications ex